Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: An evidence-based review;Microbiota, infecciones gastrointestinales, inflamación de bajo grado y antibioticoterapia en el síndrome de intestino irritable. Una revisión basada en evidencias

Revista de Gastroenterologia de Mexico

Volumn 79, Issue 2, 2014, Pages 96-134

  Schmulson, M ^a   Bielsa, M V ^b   Carmona Sanchez R ^c   Hernandez A ^d   Lopez Colombo A ^e   Lopez Vidal Y ^f   Pelaez Luna M ^a   Remes Troche, J M ^g   Tamayo, J L ^h   Valdovinos, M A ⁱ  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

^c Hospital Ángeles CMP   (Mexico)

^d INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^e INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^f UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^g UNIVERSIDAD VERACRUZANA   (Mexico)

^h UNIVERSIDAD AUTÓNOMA DE SINALOA   (Mexico)

ⁱ INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Adults; Antibiotic treatment; Bacteria overgrowth; Children; Irritable bowel syndrome; Low grade inflammation; Microbiota; Post infectious; Rifaximin; Systematic evidence based review

Indexed keywords

EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HUMAN; IRRITABLE COLON; META ANALYSIS; MICROBIOLOGY; MICROFLORA; PATHOLOGY;

EVIDENCE-BASED MEDICINE; GASTROINTESTINAL DISEASES; HUMANS; IRRITABLE BOWEL SYNDROME; MICROBIOTA;

EID: 84911115335     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rgmx.2014.01.004     Document Type: Review

References (148)

1. Hasler WL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40:21-43.
2. Ghoshal UC, Ranjan P. Post-infectious irritable bowel syndrome: The past, the present and the future. J Gastroenterol Hepatol. 2011;26 Suppl 3:94-101.
3. Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279-86.
4. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut. 2013;62:159-76.
5. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review. J Gastroenterol. 2011;46:421-31.
6. Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: The role of cytokines. Rev Esp Enferm Dig. 2010;102:711-7.
7. Rodriguez-Fandino O, Hernandez-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16:363-73.
8. Sachdev AH, Pimentel M. Antibiotics for irritable bowel syndrome: Rationale and current evidence. Curr Gastroenterol Rep. 2012;14:439-45.
9. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: An epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol. 2011;9:461-9, quiz e59.
10. Thabane M, Simunovic M, Akhtar-Danesh N, et al. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol. 2009;104:2267-74.
11. Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol. 2008;103:958-63.
12. Bonfrate L, Tack J, Grattagliano I, et al. Microbiota in health and irritable bowel syndrome: Current knowledge, perspectives and therapeutic options. Scand J Gastroenterol. 2013;48:995-1009.
13. Schmulson M, Chey WD. Abnormal immune regulation and lowgrade inflammation in IBS: Does one size fit all? [editorial]. Am J Gastroenterol. 2012;107:273-5.
14. Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother. 2012;13: 433-40.
15. Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol. 2012;107:28-35.
16. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. Disponible en: http://wwwcebmnet/indexaspx?o=5653
17. Shah ED, Basseri RJ, Chong K, et al. Abnormal breath testing in IBS: A meta-analysis. Dig Dis Sci. 2010;55:2441-9.
18. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-9.
19. Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450-2.
20. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: Comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566-70.
21. Madrid AM, Defilippi CC, Defilippi GC, et al. Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases. Rev Med Chil. 2007;135:1245-52.
22. Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802-8.
23. Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: Association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil. 2008;20:998-1008.
24. Parodi A, Dulbecco P, Savarino E, et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol. 2009;43:962-6.
25. Law D, Pimentel M. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. Dig Dis Sci. 2010;55:2302-8.
26. Park JS, Yu JH, Lim HC, et al. Usefulness of lactulose breath test for the prediction of small intestinal bacterial overgrowth in irritable bowel syndrome. Korean J Gastroenterol. 2010;56:242-8.
27. Ghoshal UC, Kumar S, Mehrotra M, et al. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil. 2010;16:40-6.
28. Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33:1059-67.
29. Yakoob J, Abbas Z, Khan R, et al. Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan. Saudi J Gastroenterol. 2011;17:371-5.
30. Rana SV, Sharma S, Kaur J, et al. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion. 2012;85:243-7.
31. Pimentel M, Kong Y, Park S. Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. Am J Gastroenterol. 2003;98:2700-4.
32. Esposito I, de Leone A, di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: An observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13:6016-21.
33. Peralta S, Cottone C, Doveri T, et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with rifaximin. World J Gastroenterol. 2009;15:2628-31.
34. Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: Are there any predictors? BMC Gastroenterol. 2010;10:23.
35. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334-40.
36. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: Relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321-9.
37. Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther. 2012;36:1084-93.
38. Scarpellini E, Giorgio V, Gabrielli M, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: A case-control study. J Pediatr. 2009;155:416-20.
39. Balsari A, Ceccarelli A, Dubini F, et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica. 1982;5:185-94.
40. Si JM, Yu YC, Fan YJ, et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol. 2004;10:1802-5.
41. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100:373-82.
42. Matto J, Maunuksela L, Kajander K, et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol. 2005;43:213-22.
43. Maukonen J, Satokari R, Matto J, et al. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol. 2006;55:625-33.
44. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24-33.
45. Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009;15:2887-92.
46. Krogius-Kurikka L, Lyra A, Malinen E, et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009;9:95.
47. Lyra A, Rinttila T, Nikkila J, et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol. 2009;15:5936-45.
48. Carroll IM, Chang YH, Park J, et al. Luminal and mucosalassociated intestinal microbiota in patients with diarrheapredominant irritable bowel syndrome. Gut Pathog. 2010;2:19.
49. Codling C, O'Mahony L, Shanahan F, et al. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci. 2010;55:392-7.
50. Noor SO, Ridgway K, Scovell L, et al. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol. 2010;10:134.
51. Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:512-9, e114-5.
52. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301:G799-807.
53. Ponnusamy K, Choi JN, Kim J, et al. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol. 2011;60:817-27.
54. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792-801.
55. Rinttila T, Lyra A, Krogius-Kurikka L, et al. Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects. Gut Pathog. 2011;3:6.
56. Saulnier DM, Riehle K, Mistretta TA, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011;141:1782-91.
57. Carroll IM, Ringel-Kulka T, Siddle JP, et al. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012;24:521-30, e248.
58. Chassard C, Dapoigny M, Scott KP, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. 2012;35:828-38.
59. Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrheapredominant irritable bowel syndrome. Neurogastroenterol Motil. 2012;24:513-20, e246-7.
60. Jeffery IB, O'Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61:997-1006.
61. Maccaferri S, Candela M, Turroni S, et al. IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation. Gut Microbes. 2012;3:406-13.
62. Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of subgroups of irritable bowel syndrome. Neurogastroenterol Motil. 2012;24:31-9.
63. Kerckhoffs AP, Ben-Amor K, Samsom M, et al. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol. 2011;60: 236-45.
64. Malinen E, Krogius-Kurikka L, Lyra A, et al. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol. 2010;16:4532-40.
65. Schwille-Kiuntke J, Frick JS, Zanger P, et al. Post-infectious irritable bowel syndrome - a review of the literature. Z Gastroenterol. 2011;49:997-1003.
66. Dai C, Jiang M. The incidence and risk factors of post-infectious irritable bowel syndrome: A meta-analysis. Hepatogastroenterology. 2012;59:67-72.
67. Haagsma JA, Siersema PD, de Wit NJ, et al. Disease burden of post-infectious irritable bowel syndrome in The Netherlands. Epidemiol Infect. 2010;138:1650-6.
68. Ji S, Park H, Lee D, et al. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol. 2005;20:381-6.
69. DuPont HL, Galler G, Garcia-Torres F, et al. Travel and travelers' diarrhea in patients with irritable bowel syndrome. Am J Trop Med Hyg. 2010;82:301-5.
70. Marshall JK, Thabane M, Garg AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59:605-11.
71. Thabane M, Simunovic M, Akhtar-Danesh N, et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010;105:933-9.
72. Pitzurra R, Fried M, Rogler G, et al. Irritable bowel syndrome among a cohort of European travelers to resource-limited destinations. J Travel Med. 2011;18:250-6.
73. Morgan DR, Benshoff M, Caceres M, et al. Irritable bowel syndrome and gastrointestinal parasite infection in a developing nation environment. Gastroenterol Res Pract. 2012;2012:ID 343812.
74. Wensaas KA, Langeland N, Hanevik K, et al. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: Historic cohort study. Gut. 2012;61:214-9.
75. Zanini B, Ricci C, Bandera F, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107:891-9.
76. Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502-13.
77. Kim HS, Kim MS, Ji SW, et al. The development of irritable bowel syndrome after Shigella infection: 3 year follow-up study. Korean J Gastroenterol. 2006;47:300-5.
78. Porter CK, Gloor K, Cash BD, et al. Risk of functional gastrointestinal disorders in U.S. military following selfreported diarrhea and vomiting during deployment. Dig Dis Sci. 2011;56:3262-9.
79. Rodriguez-Fandiño O, Hernandez-Ruiz J, Lopez-Vidal Y, et al. Intestinal recruiting and activation profiles in peripheral blood mononuclear cells in response to pathogen-associated molecular patterns stimulation in patients with IBS. Neurogastroenterol Motil. 2013;25:872-e699.
80. Okhuysen PC, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004;99:1774-8.
81. Moss-Morris R, Spence M. To ''lump'' or to ''split'' the functional somatic syndromes: Can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome? Psychosom Med. 2006;68:463-9.
82. Schwille-Kiuntke J, Enck P, Zendler C, et al. Postinfectious irritable bowel syndrome: Follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil. 2011;23: e479-88.
83. Soyturk M, Akpinar H, Gurler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol. 2007;102:1064-9.
84. Tornblom H, Holmvall P, Svenungsson B, et al. Gastrointestinal symptoms after infectious diarrhea: A five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol. 2007;5:461-4.
85. Marshall JK, Thabane M, Borgaonkar MR, et al. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol. 2007;5:457-60.
86. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of postinfectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535-44.
87. Marshall JK, Thabane M, Garg AX, et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131:445-50, quiz 660.
88. Marshall JK. Post-infectious irritable bowel syndrome following water contamination. Kidney Int Suppl. 2009;112: S42-3.
89. Matricon J, Meleine M, Gelot A, et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012;36:1009-31.
90. Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part one: The role of lymphocytes and mast cells. Rev Esp Enferm Dig. 2010;102:637-47.
91. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59:1213-21.
92. De Silva AP, Nandasiri SD, Hewavisenthi J, et al. Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting. Scand J Gastroenterol. 2012;47:619-24.
93. Weston AP, Biddle WL, Bhatia PS, et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993;38:1590-5.
94. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400-6.
95. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804-11.
96. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12:449-57.
97. Tornblom H, Lindberg G, Nyberg B, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002;123:1972-9.
98. Park CH, Joo YE, Choi SK, et al. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome. J Korean Med Sci. 2003;18:204-10.
99. Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125:1651-9.
100. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003;98:1578-83.
101. Barbara G, Stanghellini V, de Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693-702.
102. Ohman L, Isaksson S, Lundgren A, et al. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3:980-6.
103. Tunc B, Filik L, Altintas E, et al. Mucosal mast cells in irritable bowel syndrome and inflammatory bowel disease. Acta Medica (Hradec Kralove). 2005;48:163-4.
104. Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21:71-8.
105. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203-9.
106. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53:1096-101.
107. Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57: 468-73.
108. Lee KJ, Kim YB, Kim JH, et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 2008;23: 1689-94.
109. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;29:765-73.
110. Bhuiyan MR, Majumder TK, Raihan AA, et al. Histopathological alterations in post-infectious irritable bowel syndrome in Bangladeshi population. Mymensingh Med J. 2010;19: 275-81.
111. Kim HS, Lim JH, Park H, et al. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection - an observation in a small case control study. Yonsei Med J. 2010;51:45-51.
112. Goral V, Kucukoner M, Buyukbayram H. Mast cells count and serum cytokine levels in patients with irritable bowel syndrome. Hepatogastroenterology. 2010;57:751-4.
113. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: Genderdependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392-400.
114. Arevalo F, Aragon V, Montes P, et al. Increase of intraepithelial lymphocytes in patients with irritable bowel syndrome. Rev Gastroenterol Peru. 2011;31:315-8.
115. Braak B, Klooker TK, Wouters MM, et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol. 2012;107:715-26.
116. Chang L, Adeyemo M, Karagiannides I, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol. 2012;107:262-72.
117. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778-83.
118. Salzmann JL, Peltier-Koch F, Bloch F, et al. Morphometric study of colonic biopsies: A new method of estimating inflammatory diseases. Lab Invest. 1989;60:847-51.
119. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5- hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot study. Gut. 1998;42:42-6.
120. Houghton LA, Atkinson W, Whitaker RP, et al. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut. 2003;52:663-70.
121. Pimentel M, Soffer EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639-43.
122. Pimentel M, Mayer AG, Park S, et al. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003;48:86-92.
123. Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1089-95.
124. Kunkel D, Basseri RJ, Makhani MD, et al. Methane on breath testing is associated with constipation: A systematic review and meta-analysis. Dig Dis Sci. 2011;56:1612-8.
125. Furnari M, Savarino E, Bruzzone L, et al. Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. J Gastrointestin Liver Dis. 2012;21:157-63.
126. Park JH, Park DI, Kim HJ, et al. The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome. Gut Liver. 2009;3:174-9.
127. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: A systematic review and meta-analysis. Arch Med Sci. 2010;6:49-55.
128. Fumi AL, Trexler K. Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother. 2008;42:408-12.
129. Schmulson M, Chang L. Review article: The treatment of functional abdominal bloating and distension. Aliment Pharmacol Ther. 2011;33:1071-86.
130. Kwon JG, Park KS, Park JH, et al. Guidelines for the treatment of irritable bowel syndrome. Korean J Gastroenterol. 2011;57:82-99.
131. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med. 2006;145:557-63.
132. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-33.
133. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781-6.
134. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
135. Collins BS, Lin HC. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr. 2011;52:382-6.
136. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52:89-95.
137. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: Clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139-42.
138. Pimentel M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: Subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297-301.
139. Morken MH, Valeur J, Norin E, et al. Antibiotic or bacterial therapy in post-giardiasis irritable bowel syndrome. Scand J Gastroenterol. 2009;44:1296-303.
140. Weinstock LB, Fern SE, Duntley SP. Restless legs syndrome in patients with irritable bowel syndrome: Response to small intestinal bacterial overgrowth therapy. Dig Dis Sci. 2008;53:1252-6.
141. Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53:169-74.
142. Pimentel M, Morales W, Lezcano S, et al. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009;5:435-42.
143. Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci. 2011;56:2067-72.
144. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18:349-58.
145. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: Pharmacology and clinical potential. Chemotherapy. 2005;51 Suppl 1:36-66.
146. Jiang ZD, DuPont HL. Rifaximin: In vitro and in vivo antibacterial activity - a review. Chemotherapy. 2005;51 Suppl 1:67-72.
147. Gerard L, Garey KW, DuPont HL. Rifaximin: A nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005;3:201-11.
148. Debbia EA, Maioli E, Roveta S, et al. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother. 2008;20:186-94.